Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of Alport syndrome (AS) in a randomized, single-blind, placebo-controlled trial, to provide a clinical basis for the development of stem cell products for the treatment of AS, and to further clarify the therapeutic effect of hUC-MSC in the treatment of AS.

Timeline

Start

2025-01-01

Primary completion

2026-06-30

Completion

2028-12-31

Drugs

Indications